首页> 外文会议>American Peptide Symposium >Exploring the N-terminal Hydrophobic Faces of Glucagon and Glucagon-like Peptide-1
【24h】

Exploring the N-terminal Hydrophobic Faces of Glucagon and Glucagon-like Peptide-1

机译:探索胰高血糖素和胰高血糖素肽-1的N-末端疏水面

获取原文

摘要

Glucagon, Glucagon-like Peptide-1 (GLP-1), as well as human (hCT) and salmon calcitonin (sCT) are all members of the secretin family of hormones that act on distinct G protein-coupled receptors in what are believed to be largely α-helical conformations [1-5]. Approximately 50% sequence homology exists between the two glucagon-related peptides and among the two calcitonins. The amino acid sequences and α-helical projections of these four peptides reveals a strong sequence and structural similarity between three N-terminal hydrophobic residues in GLP-1 (F~5, V~(10) and Y~(13)) and glucagon (F~6, Y~(10) and Y~(13)) and a set of equally-spaced, aromatic residues in hCT (Y~(12), Y~(16) and F~(19)). The sCT sequence differs from this trend with a triad of leucine residues (L~(12), L~(16) and L~(19)). Structural studies have indicated that both of these regions (6, 10, 13 for glucagon & GLP-1 and 12, 16, 19 in hCT & sCT) exhibit a-helical secondary structure. This structure is purported to be the most probable receptor-active conformation for these two regions [2-5]. Fowler et al. (2005) reported the characterization of hCT-sCT chimeric peptides [11. Most crucial to the design of our study was a H~(17)R-hCT peptide substituted with residues K~(11) , L~(12), E~(13), L~(16) and L~(19) of sCT. The resulting peptide (6CH-R) showed a ten-fold increase in receptor binding potency and a two-fold increase in cAMP production when compared to native hCT. This hCT analog was reported to be equipotent with sCT [1]. Given these results and the structural similarities in the aromatic regions of CT and the glucagon-related peptides, we questioned whether a L~6, L~(10) and L~(13) variant of GLP-1 or glucagon would provide an analog with enhanced receptor potency. We characterized this assertion as the leucine hypothesis. The strategy was two-fold; if L~(6,10,13) analogs proved more potent in vitro we would explore the possibility of using aliphatic residues at these positions, and if not, we would determine the extent that these three residues could be modified with aromatic character.
机译:胰高血糖素,胰高血糖素样肽-1(GLP-1),以及人(HCT)和鲑鱼降钙素(SCT)是激素的分泌家族的所有成员在了被认为是作用于不同的G蛋白偶联受体在很大程度上α螺旋构象[1-5]。大约50%的序列同源性在两个胰高血糖素相关的肽之间和两个降钙素之间存在。的氨基酸序列和这四种肽的α螺旋突起揭示了GLP-1(F〜5,V〜(10)和Y〜(13))和胰高血糖素三个N-末端疏水残基之间的强的序列和结构相似性(F〜6,Y〜(10)和Y〜(13))和在降钙素一组等间隔的,芳族的残基(Y〜(12)中,Y〜(16)和F〜(19))。从这一趋势在SCT序列不同用亮氨酸残基的三联体(L〜(12)中,L〜(16)和L〜(19))。结构研究已表明,这两个区域(6,10,13为胰高血糖素和GLP-1和12,16,19中的hCT&SCT)的呈现α-螺旋二级结构。这种结构被声称是为这两个区域[2-5]的最可能的受体活性构象。福勒等人。 (2005)报道HCT-鲑鱼降钙素嵌合肽[11表征。最关键的我们的研究的设计是一个H〜(17)R-的hCT肽取代残基K〜(11)中,L〜(12)中,E〜(13),L〜(16)和L〜(19 )的SCT。将得到的肽(6CH-R)显示在受体结合效力的十倍增加,并且当与天然降钙素在cAMP产生的两倍的增加。据报道这降钙素类似物与sCT的[1]被等效。鉴于这些结果和结构相似性在CT的芳香族区域和胰高血糖素相关的肽,我们怀疑GLP-1或胰高血糖素的L〜6,L〜(10)和L〜(13)的变体是否将提供一个模拟具有增强的受体效能。我们的特点这一论断为亮氨酸假说。该战略是双重的;如果L〜(6,10,13)类似物证明在体外更有效的,我们将探讨使用的脂族残基在这些位置的可能性,以及如果没有,我们将确定的范围内,这些三个残基可以与芳族特性进行修改。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号